Tivdak Approved for Recurrent or Metastatic Cervical Cancer
The Food and Drug Administration has granted accelerated approval to Tivdak (tisotumab vedotin-tftv) for the treatment of adults with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. Tivdak is a tissue…